CompletedNCT00107731
Quetiapine with lithium or divalproex for maintenance treatment in bipolarity
About this title
Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
Read the official source — NCT00107731This study evaluated the safety and effectiveness of quetiapine fumarate for people with bipolarity.
Medication studyAges 18+Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of quetiapine fumarate for people with bipolarity.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 165 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 710
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, France, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT00107731
- Official title
Show the full official title
A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Valproate) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients (Abbreviated)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedBirmingham, United States · Beverly Hills, United States · Chula Vista, United States
165 more locations
- Redlands, United States
- San Francisco, United States
- Santa Ana, United States
- Gainesville, United States
- Jacksonville, United States
- Miami, United States
- Sarasota, United States
- Tampa, United States
- Winter Park, United States
- Granite City, United States
- Libertyville, United States
- Schaumburg, United States
- Wichita, United States
- Metairie, United States
- Glen Burnie, United States
- Kalamazoo, United States
- Saint Charles, United States
- St Louis, United States
- Brooklyn, United States
- Olean, United States
- Rochester, United States
- Morganton, United States
- Raleigh, United States
- Oklahoma City, United States
- Portland, United States
- Havertown, United States
- Media, United States
- Philadelphia, United States
- Conroe, United States
- Houston, United States
- Richmond, United States
- Seattle, United States
- Milwaukee, United States
- Greenwich, Australia
- Brisbane, Australia
- Everton Park, Australia
- Southport, Australia
- Glenside, Australia
- Box Hill, Australia
- Dandenong, Australia
- Epping, Australia
- Richmond, Australia
- Assebroek, Belgium
- Brussels, Belgium
- Ghent, Belgium
- Kortenberg, Belgium
- Manage, Belgium
- St-Denijs-Westrem, Belgium
- Waregem, Belgium
- Kardzhali, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Jeseník, Czechia
- Litomolice, Czechia
- Olomouc, Czechia
- Prague, Czechia
- Pterova, Czechia
- Espoo, Finland
- Harjavalta, Finland
- Helsinki, Finland
- Kellokoski, Finland
- Seinäjoki, Finland
- Besançon, France
- Bourg-en-Bresse, France
- La Rochelle, France
- Marseille, France
- Montpellier, France
- Nîmes, France
- Paris, France
- Strasbourg, France
- Toulouse, France
- Augsburg, Germany
- Berlin, Germany
- Cologne, Germany
- Heidelberg, Germany
- Homburg, Germany
- München, Germany
- Regensburg, Germany
- Saarbrücken, Germany
- Budapest, Hungary
- Füzesabony, Hungary
- Győr, Hungary
- Kecskemét, Hungary
- Kistarcsa, Hungary
- Pécs, Hungary
- Bari, Italy
- Bergamo, Italy
- Brescia, Italy
- Cagliari, Italy
- Civitanova Marche, Italy
- Florence, Italy
- Genova, Italy
- La Spezia, Italy
- Milan, Italy
- Naples, Italy
- Padova, Italy
- Pisa, Italy
- Roma, Italy
- Siena, Italy
- Trieste, Italy
- Bergen, Norway
- Bodø, Norway
- Bryne, Norway
- Namsos, Norway
- Oslo, Norway
- Ottestad, Norway
- Skien, Norway
- Bialystok, Poland
- Bydgoszcz, Poland
- Choroszcz, Poland
- Gdansk, Poland
- Gorlice, Poland
- Janów Lubelski, Poland
- Krakow, Poland
- Lipno, Poland
- Lodz, Poland
- Lublin, Poland
- Nowy Targ, Poland
- Poznan, Poland
- Starogard Gdański, Poland
- Szczecin, Poland
- Torun, Poland
- Warsaw, Poland
- Zubki, Poland
- Moscow, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Bloemfontein, South Africa
- Durban, South Africa
- Johannesburg, South Africa
- Krugersdorp, South Africa
- Pretoria, South Africa
- Barcelona, Spain
- Terrassa, Spain
- Puerto Real, Spain
- Granada, Spain
- Madrid, Spain
- Oviedo, Spain
- Langreo, Spain
- Seville, Spain
- Bilbao, Spain
- Guadalajara, Spain
- Santiago de Compostela, Spain
- Vigo, Spain
- Falköping, Sweden
- Linköping, Sweden
- Ludvika, Sweden
- Sollentuna, Sweden
- Stockholm, Sweden
- Sundsvall, Sweden
- Adana, Türkiye
- Ankara, Türkiye
- Istanbul, Türkiye
- Izmir, Türkiye
- Birmingham, United Kingdom
- London, United Kingdom
- Oxford, United Kingdom
- Runcorn, United Kingdom
- Ryhope, United Kingdom
- Surbiton, United Kingdom
- Welwyn Garden City, United Kingdom
- Czechia
- Russia
- Türkiye
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of quetiapine fumarate for people with bipolarity.
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including quetiapine fumarate, lithium and divalproex.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
"A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by ...
Aripiprazole added to divalproex for treatment-resistant bipolar depression